Table 3.

Laboratory Abnormalities: Grade 3 or 4

Laboratory AbnormalityDual Therapy (n = 126)Triple Therapy (n = 123)P Value
Any grade 3 or 4 laboratory abnormality 4 (3)4 (3).972
Alanine aminotransferase (>5 ×ULN)00
Aspartate aminotransferase (>5 ×ULN)01 (1).310
Total cholesterol (>300 mg/dL)4 (3)3 (2).725
Triglycerides (>750 mg/dL)00
Laboratory AbnormalityDual Therapy (n = 126)Triple Therapy (n = 123)P Value
Any grade 3 or 4 laboratory abnormality 4 (3)4 (3).972
Alanine aminotransferase (>5 ×ULN)00
Aspartate aminotransferase (>5 ×ULN)01 (1).310
Total cholesterol (>300 mg/dL)4 (3)3 (2).725
Triglycerides (>750 mg/dL)00

Data are number of patients with 1 or more adverse events (%).. Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitors.

Abbreviation: ULN, upper limit of normal.

Table 3.

Laboratory Abnormalities: Grade 3 or 4

Laboratory AbnormalityDual Therapy (n = 126)Triple Therapy (n = 123)P Value
Any grade 3 or 4 laboratory abnormality 4 (3)4 (3).972
Alanine aminotransferase (>5 ×ULN)00
Aspartate aminotransferase (>5 ×ULN)01 (1).310
Total cholesterol (>300 mg/dL)4 (3)3 (2).725
Triglycerides (>750 mg/dL)00
Laboratory AbnormalityDual Therapy (n = 126)Triple Therapy (n = 123)P Value
Any grade 3 or 4 laboratory abnormality 4 (3)4 (3).972
Alanine aminotransferase (>5 ×ULN)00
Aspartate aminotransferase (>5 ×ULN)01 (1).310
Total cholesterol (>300 mg/dL)4 (3)3 (2).725
Triglycerides (>750 mg/dL)00

Data are number of patients with 1 or more adverse events (%).. Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitors.

Abbreviation: ULN, upper limit of normal.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close